Plasma Protein Therapeutics Association
The Plasma Protein Therapeutics Association (PPTA) is a dynamic trade association that
represents a unique sector of the biologics and biotechnology industry. PPTA represents
more than 1,000 human plasma collection centers in North America and Europe, as well as
the manufacturers of lifesaving plasma protein therapies. Our members produce
approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA also administers standards and programs that help ensure the quality and safety of
plasma collection and manufacturing and protect both donors and patients.
--------------------------------------
The International Plasma and Fractionation Association (IPFA)
IPFA is the association for not-for-profit plasma organizations.
IPFA is The International Plasma and Fractionation Association.
(IPFA) is an association representing organizations engaged in the collection of plasma
and fractionation of it into plasma-derived medicinal products.
IPFA´s members are from the not-for-profit sector and come from all over the world. They
represent both blood establishments collecting plasma and manufacturers (fractionators)
who produce plasma-derived products.
IPFA´s aim is to enable robust, safe supply and patient access to life-saving plasma-
derived medicines while strengthening the contribution and ability of the public sector to
collect plasma within their communities for this purpose.
We encourage and help the not-for-profit blood establishment to increase their collection
of plasma for fractionation and their aims to conduct this task alongside the collection of
other blood components, with a strong emphasis on donations without financial gain,
donor health protection, and long-term commitment.
Plasma is a strategic resource for plasma-derived medicines, needed all over the world. By
focusing on the local and regional collection of plasma and its use to produce medicines
for the same community, the combined efforts become an integral part of a public health
system and bring health value to patients. This way countries and regions can reach a
better level of strategic independence for both plasma and plasma-derived medicines,
which is both sustainable and plays a key role in contingency planning
--------------------------------------
CSL is a leading global biotechnology company
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving
medicines, including those that treat hemophilia and immune deficiencies, as well as
vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise
to save lives using the latest technologies. Today, CSL – including our three businesses,
CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in
more than 100 countries and employs 30,000 people.
--------------------------------------
--------------------------------------
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma
--------------------------------------
is a leading Chinese biopharmaceutical
--------------------------------------
Recognising the importance of plasma and with over 60 years of experience in the industry, BPL supplies high-quality plasma-derived
--------------------------------------
www.jbpo.or.jp/english
JB is a general incorporated association formed by the integration of the plasma fractionation operation
.png)
--------------------------------------
www.raas-corp.com
--------------------------------------
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company.
--------------------------------------
With advanced research, we create innovative vaccines and bio-therapeutics for a healthier tomorrow.
--------------------------------------
